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Purpose: Because evasion of tumor suppression is a critical step
in cancer development, cancer cells have developed a variety of
mechanisms to circumvent the influence of tumor suppressive
pathways. Thus, genes that negatively regulate tumor suppressors
could be considered novel types of oncogenes such as Bmi-1
repressing p16Ink4a and inhibiting p53 and were found to be
frequently up-regulated in a variety of cancers. p38 mitogen-
activated protein kinase (MAPK), which reportedly plays a cru-
cial role as a tumor suppressor, is activated in number of lung
adenocarcinomas, which is seemingly at odds with its role as a
tumor suppressor.
Methods: We examined 10 lung adenocarcinomas and corre-
sponding normal tissues and determined the expression levels of
a variety of tumor suppressor proteins through real-time poly-
merase chain reaction and immunohistochemistry and measured
p38 MAPK activity by immunoblotting or immunohistochemistry
analysis. In the in vitro cellular model, p38 activation by H-Ras
and consequent senescence induction was achieved through retro-
viral gene transduction. Similarly, the suppression of p16Ink4a
by Bmi-1 after the introduction of H-Ras was achieved through
transient transfection with cationic liposome.
Results: We detected several lung adenocarcinomas that were
positive for activated p38 MAPK but evidenced reduced levels of
p16Ink4a expression. The suppression of p16Ink4a occurred in
parallel with an increase in Bmi-1 and/or p16Ink4a promoter
hypermethylation. Consistent with these observations, the H-Ras-
stimulated induction of p16Ink4a was suppressed significantly
through the coexpression of Bmi-1 in vitro.
Discussion: These results demonstrate that the suppression of
p16Ink4a by either the induction of Bmi-1 or the hypermethyl-
ation of p16Ink4 may be an important step in avoiding tumor
surveillance by p38 MAPK during the development of lung
cancer.
Key Words: Lung adenocarcinoma, p38 activation, p16Ink4a,
Bmi-1, Methylation.
(J Thorac Oncol. 2011;6: 423–431)
Lung cancer is one of the primary causes of cancer-related deaths worldwide.1 The majority of lung cancers
are non-small cell lung carcinomas (NSCLCs), which can
be characterized further into three major histologic sub-
types: squamous cell carcinoma, adenocarcinomas, and
large cell lung carcinoma.2 Among the three types of
NSCLC, adenocarcinoma is the most common and is the
least clearly associated with smoking.3 p38 is a member of
the family of mitogen-activated protein kinases that in-
cludes extracellular signal-regulated kinase and c-Jun
N-terminal kinase. p38 primarily transduces a variety of
stress stimuli, including ultraviolet (UV), oxidative, and
oncogenic stresses in the regulation of diverse stress re-
sponse pathways.4 In particular, p38 is activated by strong
oncogenic stimuli, such as H-Ras, and transduces senes-
cence signals, leading to premature cell senescence or cell
cycle arrest.5 A growing body of evidence suggests that the
induction of p16Ink4a and the transcriptional activation of
p53 are major effectors of oncogenically induced senes-
cence (OIS) mediated by p38 in response to oncogenic
stimulation.6–8 On the contrary, despite well-established
role of p38 in antiproliferative function, p38 in some cases
functions as positive regulator of proliferation in hemato-
poietic cells and cancer cells, whose proliferation was
affected by p38 chemical inhibitors.9–13 Nevertheless, the
tumor suppressor function of p38 is highly supported by
the recent reports demonstrating that several negative
regulators of p38 signaling is frequently overexpressed in
human cancers such as the phosphatase PPM1D14,15 and
DUS2616 and glutathione S transferase Mu 1 and 2.17
Nevertheless, in a seeming contradiction to many of the in
vitro results reported thus far, many NSCLCs exhibit
activated p38.18,19 Thus far, the mechanism by which
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NSCLC persists with high levels of activated p38 remains
to be clarified, considering that p38 evidences such pro-
found tumor-suppressive qualities.
In a fashion similar to that noted with other tumor
suppressors, the expression of p16Ink4a, which has been
identified as an effecter of p38 in the induction of OIS, is
suppressed in a variety of human lung cancers, including
NSCLC.20–22 This p16Ink4a suppression may be attribut-
able to frequent methylation of the p16Ink4a promoter
region.23,24 Nevertheless, Bmi-1, a polycomb protein that
targets the INK4a locus (which encodes for p16Ink4a and
p19Arf) and represses the expression of p16Ink4a, has
been shown to be highly expressed in lung cancers.25–27
In this study, we evaluated 10 lung adenocarcinoma
specimens and determined that p38 was activated in six of
them, independent of patient age and gender.18 Interest-
ingly, p16Ink4a expression was not induced in 6 of the 10
samples. The induction of Bmi-1 or the methylation of the
p16Ink4a promoter occurred in parallel with the failure of
p16Ink4a induction in NSCLCs, consistent with our in
vivo results. Our results implied that lung adenocarcino-
mas with defective p16Ink4a induction under oncogenic
stress conditions might be closely associated with the
subsequent deregulation of tumor suppression through
Bmi-1 expression and/or p16Ink4a promoter methylation.
MATERIALS AND METHODS
Patient Sample Collection
Tissue specimens (cancerous and corresponding nor-
mal tissue) were obtained from 10 patients (eight men and
two women; median age, 65 years; range, 43–78) (Table 1)
who had undergone surgery at the CHA hospital. The
approval of the institutional review board was obtained
before sample acquisition.
Cell Culture and Gene Delivery
Mouse embryonic fibroblasts (MEFs) and 293 T cells
were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and penicillin
(100 U/ml)/streptomycin (100 g/ml) at 37°C in 5% CO2.
Transient expression in the 293 T cells was conducted
using Lipofectamine 2000 (Invitrogen, San Diego, CA), in
accordance with the manufacturer’s instructions. Stable
H-Ras expression in MEFs was achieved through a retro-
viral gene delivery technique, as described previously.28
Immunoblotting
Total protein lysates from cell lines and tissue were
separated by SDS-PAGE in accordance with the standard
protocols (described elsewhere), and immunoblotting was
performed with a broad variety of antibodies. Antiphos-
phorylated p38 (cat # 4631S) was purchased from Cell
Signaling Technology. Anti--actin (cat #SC-47778), anti-
H-Ras (cat # SC-520ß), and antiextracellular signal-regu-
lated kinase 2 (cat # SC-154) antibodies were purchased
from Santa Cruz Biotechnology, Inc. Anti-Bmi-1
(ab14389) and anti-PPM1D (A300-66A) antibodies were
acquired from Abcam (Cambridge, MA) and Bethyl Lab-
oratories, Inc. (Montgomery, TX), respectively.
-Galactosidase Staining
The -galactosidase staining was conducted in ac-
cordance with the manufacturer’s recommended protocols
(Cat# 9860; Cell Signaling Technology). After -galacto-
sidase staining, the cells were counterstained with 4,
6-diamidino-2-phenylindole (0.2 g/ml in PBS) to visual-
ize the nuclei.
RNA Isolation and Quantitative Real-Time
Polymerase Chain Reaction
Total RNA was extracted from cells with TRIzol Reagent
(Invitrogen) and then treated with DNase I, in accordance with
the manufacturer’s instructions. TRIzol was removed by the
addition of chloroform, and messenger RNA (mRNA) was
precipitated using isopropanol. The RNA precipitates were
washed with 75% ethanol. Gene-specific primers were designed
to amplify the genes for p21, p16Ink4a, Bmi-1, Gadd45, and the
housekeeping protein, glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH). Primer sequences were as follows:
for p21, 5-GCGATGGAACTTCGACTTTG-3 and 5-ACAG-
GTCCACATGGTCTTCC-3; for p16Ink4a, 5-GCCTTTTCA-
CTGTGTTGGAG-3 and 5-TGCCATTTGCTAGCAGTGTG-3;
for Bmi-1, 5-CCAGGGCTTTTCAAAAATGA-3 and 5-CCGA-
TABLE 1. Clinical and Histologic Features and Molecular Alterations in Patient Adenocarcinoma Samples
Case No. Sex Age (yr)
Current
Smoker Stage pP38 pMK2 p16 Bmi-1
P16
Methylation
1 F 49 N T2N0M0     
2 F 71 N T3N0M0     
3 M 68 Y T4N2M0     
4 M 46 N T1N0M0    n/s 
5 M 46 N T2N1M0     
6 M 43 N T2N2M0     
7 M 77 N T1N0M0     
8 M 78 Y T2N0M0     
9 M 68 N T2N0M0     
10 M 62 N T2N0M0    n/s 
n/s, non specified.
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TCCAATCTGTTCTGGT-3; and for GAPDH, 5-TGCGAGAAC-
GACATCAACAT-3 and 5-TCCCGGCAAAAACAAATAAG-3.
Amplification reactionswere conducted in final reaction volumes of
20 ml, each containing 1 SYBR supermix, 500 nmol/liter of each
gene-specific primer, and 2 ml of template. The thermal cycling
parameters were as follows: initial denaturation at 95°C for 1
minute, followed by 45 cycles of 95°C for 15 seconds, 58°C for 15
seconds, and 72°C for 15 seconds, with a final extension at
72°C for 5 minutes. After amplification, baseline and thresh-
old levels for each reaction were determined using propri-
etary software (Mastercycler ep realplex, Eppendorf). Real-
time polymerase chain reaction (PCR) was conducted using a
LightCycler 480 Real-Time PCR system (Roche Applied
Science, Indianapolis, IN).
Methylation-Specific PCR
Genomic DNA was extracted with a G-spin Genomic
DNA Extraction Kit (#17041; iNtRON Biotechnology). Bisul-
fite-modified genomic DNA was generated as described previ-
ously29 and subsequently amplified with either methylation-
specific or nonmethylation-specific primer sets for p16Ink4a,
also as described previously.30 The sequences of the primers
were as follows: nonmethylation-specific, 5-TTATTA-
GAGGGTGGGGTGGATTGT-3 (forward) and 5-CAAC-
CCCAAACCACAACCATAA-3 (reverse); methylation-spe-
cific, 5-TTATTAGAGGGTGGGGCGGATCGC-3 (forward)
and 5-GACCCCGAACCGCGACCGTAA-3 (reverse).
Statistical Analysis
The graphical data were expressed as means  SD.
Statistical significance among the three groups and be-
tween-groups was assessed through Student’s t tests. Sig-
nificance was assumed at p  0.05 (*) and p  0.01 (**).
Statistical analyses were conducted using the SAS statistical
package, v.9.13 (SAS Inc., Cary, NC; http://www.sas.com/).
RESULTS
p16Ink4a Suppression in Lung
Adenocarcinoma
Table 1 summarizes the clinical and histologic fea-
tures of 10 lung adenocarcinoma samples and correspond-
ing normal tissues. On the basis of previous reports, we
hypothesized that the failure of tumor suppressive mech-
anisms on oncogenic stimulation would be the principal
cause of lung cancer development.31,32 Thus, we evaluated
the expression of p16Ink4a and p53 transcriptional activity
(i.e., the expression of the downstream targets p21 and
Gadd45a), both of which have been implicated as key
mediators of signaling in OIS.33–35 As shown in Figure 1A,
p16Ink4a mRNA failed to be induced in 6 of 10 adeno-
carcinoma samples, when compared with the normal tissue
counterparts (Figure 1A). Nevertheless, Gadd45a and p21,
both of which are well-established downstream targets of
p53, were each down-regulated in two adenocarcinoma
samples (Figures 1B, C).
P38 Activation in Lung Adenocarcinoma
Considering that the expression of p16Ink4a is reg-
ulated, in part, by p38 activity,36 we hypothesized that the
suppression of p16Ink4a expression in the lung adenocar-
cinomas may have been attributable to a disruption of p38
signaling.6,8 To evaluate the p38 activity, we measured the
phosphorylated levels of p38 and mitogen-activated pro-
tein kinase-activated protein kinase 2 (phospho-MK2)—a
well-established p38 substrate37—for immunoblotting
FIGURE 1. Relative mRNA levels of tumor suppressors in
lung tumor tissue, when compared with normal lung tis-
sue. mRNA levels of the indicated tumor suppressors were
determined by semiquantitative real-time PCR analysis.
Graphic representation of quantified data (fold change
when compared with normal tissue) is also shown.
p16Ink4a (A), Gadd45a (B), and p21 (C). mRNA, messen-
ger RNA; PCR, polymerase chain reaction.
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analyses. Each phosphorylation level was then quantified
(Figures 2B, C). Interestingly, the 10 lung adenocarcinoma
samples (T in Figure 2A) all exhibited high Mcm7 levels,
consistent with the previous report,38 six lung adenocarci-
nomas exhibited high levels of p38 activity in comparison
with their normal counterparts (Figures 2A, B). Phosphory-
lated MK-2 was detected in 7 of 10 lung adenocarcinomas
(Figure 2C). The analysis of active p38 using immunohisto-
chemistry (IHC) demonstrated that phosphorylated p38 was
present in 8 of the 10 lung adenocarcinomas (Figure 2C, and
data not shown). Therefore, we concluded that p38 was
activated in six of the lung adenocarcinomas that were com-
monly positive to phospho-p38 and phospho-MK2 immuno-
blots, and phospho-p38 IHC (* in Figure 2B).
p16Ink4a expression was not induced in three of the six
adenocarcinomas, even under significantly high p38 activity
conditions (Figure 1A). These results indicated that the inci-
dence of lung adenocarcinoma might parallel the disruption
of p16Ink4a expression.
The Role of p38 in Ras-Induced Senescence
To confirm the role of p38 in OIS, we used p38
knock-in (KI) (p38KI/) MEFs. The levels of p38 activity
in p38KI/ MEFs were lower than in the wild-type (wt)
MEFs, and p38KI/ MEFs proved more susceptible to
oncogenic challenge.39 Consistently, the phosphorylation
of p38 in p38KI/ MEFs was less sensitive to UV-induced
stress, when compared with the wt MEFs (Figure 3A). We
subsequently evaluated the effects of oncogenic challenge
with H-Ras on wt and p38KI/ MEFs. As demonstrated in
Figure 3B, the introduction of H-Ras into wt MEFs re-
sulted in the induction of senescence, as determined by
positive -galactosidase staining (Figure 3B, blue arrows).
By way of contrast, no senescent cells were detected in the
H-Ras-stimulated p38KI/ MEFs. At higher magnification,
we detected senescent cells that were positive for  galac-
tosidase only in the wt MEFs in the presence of H-Ras
(Figure 3C, top panel, black arrows); this result clearly suggests
FIGURE 2. Activation of p38 MAPK in lung adenocarcinomas. A, p38 MAPK activity was determined by immunoblot
analysis using antiphospho-p38 (pp38, upper panel) and antiphospho-MK2 (pMK2, middle panel) antibodies in the 10
patient samples (N, normal; T, tumor). Equal protein loading was verified by analysis of ERK2 (bottom panel). Lung ade-
nocarcinoma samples were all positive to anti-Mcm7 antibody (top panel). B, Intensities of the bands corresponding to
pp38 (as an indication of p38 activation) and pMK2 (as an indication of p38 activity) were measured using NIH imager J
software (http://rsb.info.nih.gov/ij/) and are presented in graphical form (* indicates samples with commonly positive to
pp38, pMK2 and pp38 IHC). C, Human lung tissues (normal and/or cancer) were subjected to IHC using an antipp38 anti-
body. The regions of lung adenocarcinoma indicated by the dotted line were clearly positive (left panel). Magnified normal
lung alveolar tissues (middle panel) and lung adenocarcinoma tissues (right panel) are shown (100 magnification). Normal
lung alveolar tissues were negative for pp38 MAPK staining. MAPK, mitogen-activated protein kinase; ERK2, extracellular
signal-regulated kinase 2; IHC, immunohistochemistry.
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that p38 performs a critical function in OIS on oncogenic
challenge by H-Ras. The p38 activation induced by H-Ras
oncogenic stress was measured by immunoblotting for phospho-
p38. Consistently, the activation of p38 in the p38KI/ MEFs
was comparably lower under H-Ras oncogenic stress when
compared with that noted in the wt MEFs (Figure 3D).
Bmi-1 Induction and p16Ink4a Methylation in
Lung Adenocarcinoma
Considering that p38 performs an important role in
tumor suppression in response to oncogenic stress, lung
adenocarcinomas evidencing activated p38 might have
developed additional mechanisms to escape p38-dependent
tumor suppression, such as the suppression of p16Ink4a
(Figure 1A). In this fashion, the circumvention of normal
tumor suppressive mechanisms governed by p38 can result
in the initiation of tumorigenesis on oncogenic challenge.
Bmi-1 is a transcriptional repressor of p16Ink4a, which is
expressed abundantly in lung cancers.25–27,40 To assess
whether the observed reductions in p16Ink4a expression
were induced by increased Bmi-1 expression, we evaluated
Bmi-1 expression levels in lung cancer specimens (Figure
3A). Four of the six lung adenocarcinomas with suppressed
p16 expression exhibited high Bmi-1 expression levels
(patients 5, 6, 8, and 9, Figure 4A and Table 1). IHC
analyses demonstrated that Bmi-1 was abundantly ex-
pressed in 7 of 10 adenocarcinomas, when compared with
normal lung tissues (Figure 4B and data not shown).
Consistent with these findings, Bmi-1 expression levels
were negatively correlated with active p38 and reduced
p16Ink4a expression in all three of the lung adenocarci-
nomas (pat# 5, 6, and 9, Figure 4A and Table 1). p16Ink4a
promoter hypermethylation leading to p16Ink4a suppres-
sion has been previously detected in a variety of can-
cers.20,24,26,41 We also assessed the levels of p16Ink4a
promoter methylation in lung tumor samples through
methylation-specific PCR. Among the six samples evi-
dencing p16Ink4a suppression (pat# 1, 2, 5, 6, 8, and 9),
one sample (pat# 1) exhibited significantly greater
p16Ink4a promoter methylation, when compared with the
normal tissues (Figure 4C). These results demonstrated
that in lung adenocarcinomas with activated p38, p16Ink4a
suppression is associated closely to either the induction of
Bmi-1 or the methylation of the p16Ink4a promoter.
Ectopic Expression of Bmi-1 Attenuates
H-Ras-Induced p16Ink4a Expression
Because Bmi-1 up-regulation and p16Ink4a suppression
in lung adenocarcinomas seemed to be linked to p38 activation,
we attempted to determine whether the ectopic expression of
Bmi-1 could repress the expression of p16Ink4a under onco-
genic stimulation conditions. HEK293T cells were transfected
FIGURE 3. Requirement for p38
MAPK in OIS. A, p38 phosphoryla-
tion (p-P38) was compared be-
tween wt MEFs and p38KI/ MEFs
under 30 mJ/cm2 of UVB.  actin
for loading control. B, H-Ras-in-
duced senescence in MEFs was de-
termined by -galactosidase stain-
ing. Blue arrows indicate
-galactosidase-positive cells. C,
Higher magnification images (40
magnification) are shown with DAPI
counterstaining. Black arrows indi-
cate -galactosidase-positive cells.
D, p38 activation on H-Ras stable
expression was determined in wt
MEFs and p38KI/ MEFs by immu-
noblotting for phospho-p38. p38
immunoblotting for loading control.
MEF, mouse embryonic fibroblasts;
UVB, ultraviolet B; DAPI, 6-dia-
midino-2-phenylindole; wt, wild
type; OIS, oncogenically induced
senescence.
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with expression vectors for either Bmi-1 or Wip1 (wt p53
inducible phosphatase, encoded by PPM1D), which has been
negatively correlated with p16Ink4a levels,8 in the absence or
presence of coexpressed H-Ras. The levels of the p16 protein
were increased significantly by H-Ras-mediated oncogenic stim-
ulation (lane 4 versus lane 1) but were significantly reduced on
the coexpression of either Wip1 or Bmi-1 (lane 4 versus lanes 5
and 6) (Figure 5A). Considering the relatively high protein
FIGURE 4. Elevated Bmi-1 or/and p16Ink4a
methylation in lung adenocarcinoma. A, Fold
change in Bmi-1 mRNA levels in lung adenocar-
cinoma, when compared with normal tissues. B,
Bmi-1 levels in normal and cancer tissues (left
panel), normal tissue (middle panel), and can-
cer tissue (right panel) were analyzed by IHC.
Normal lung alveolar and bronchial tissues were
negative for Bmi-1 staining (middle panel). The
glandular structure with brown-colored nuclear
staining represents lung adenocarcinoma (right
panel). C, p16Ink4a promoter methylation levels
were determined by MSP analysis (U, unmethyl-
ated; M, methylated). *p16Ink4a promoter
methylation. mRNA, messenger RNA; IHC, im-
munohistochemistry; MSP, methylation-specific
polymerase chain reaction.
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stability of p16 (half life: 8 hours),42 these significant reductions
in the levels of the p16 protein may be induced by the suppres-
sion of mRNA transcription. As anticipated, reduced levels of
p16Ink4a mRNA in the presence of Bmi-1 and H-Ras were
confirmed by real-time PCR (Figure 5B). These results clearly
indicated that p38 can be activated in response to oncogenic
challenge and can function as a “sensor” of oncogenic stress but
that the induction of Bmi-1 and abrogation of downstream
effectors such as p16Ink4a may compromise the tumor-suppres-
sive mechanisms activated by p38.
DISCUSSION
The role of p38 as an important tumor suppressor has
been demonstrated in a number of previous in vitro stud-
ies.5,6,14,43,44 The activation of p38 in response to onco-
genic stimulation induces senescence or apoptosis, thereby
protecting cells against tumorigenesis. The abrogation of
the p38 tumor suppressive pathway may constitute a piv-
otal event in the induction of tumorigenesis. For example,
Wip1, a p38 phosphatase, is frequently amplified in human
breast and ovarian cancers, thereby resulting in defective
p38 activation.14,45 Nevertheless, several independent
studies have demonstrated the activation of p38 in lung
cancers.18,19 The development and persistence of lung
cancer cells with strong p38 activity, which would nor-
mally result in OIS or apoptosis, indicates that key down-
stream signaling events in p38-mediated tumor suppres-
sive pathways are defective in lung cancers featuring high
p38 activity. In this study, we demonstrated that the
expression of p16Ink4a, which has been implicated in OIS
in a number of cellular models,33,46,47 is impaired signifi-
cantly in lung cancers in which p38 activity is relatively
high. This suppression of p16Ink4a paralleled the observed
increases in p16Ink4a promoter methylation and Bmi-1
induction in part (Table 1). Interestingly, reduced
p16Ink4a expression was noted in three of six lung cancer
specimens evidencing high p38 activity (Table 1), thus
suggesting that the abrogation of p38-mediated tumor
suppressive mechanisms can be achieved, at least in part,
through the suppression of p16Ink4a expression. Further-
more, our results demonstrated that cells in which
p38-dependent tumor suppressive mechanisms were in-
duced in response to oncogenic challenge were not pro-
tected because of the abrogation of p16Ink4a mediated
either by the induction of Bmi-1 or by the methylation of
p16Ink4a (Figure 6). This notion was supported by the
in vitro finding that ectopic Bmi-1 expression significan-
tly represses H-Ras-induced p16Ink4a expression (Figures
5A, B).
Thus far, a number of independent studies have
reported that p16Ink4a hypermethylation and the subse-
quent suppression of mRNA expression can occur in lung
cancer cell lines and/or in specimens obtained from pa-
tients with lung cancer.22,24,48–50 Bmi-1, a known transcrip-
tional repressor of p16Ink4a, is expressed abundantly in
NSCLCs, and Bmi-1 expression is negatively correlated
with the expression of p16Ink4a; this is consistent with our
findings.25 It is also worth mentioning that we demon-
strated that the suppression of p16Ink4a by Bmi-1 in lung
cancer occurs in the presence of p38 activation (Table 1).
Thus, the induction of Bmi-1 and the subsequent suppres-
sion of p16Ink4a in the presence of p38 activation in lung
cancer cells represent a novel mechanism of cellular avoid-
ance of p38 tumor surveillance during the development of
lung cancer. Alternatively, homozygous deletion of
FIGURE 5. Suppression of p16Ink4a expression by Bmi-1 in
vitro. A, Protein expression of p16Ink4a under the indicated
conditions was determined by immunoblot analysis using an
antip16 antibody (top panel). Wip1, Bmi-1, and H-Ras ex-
pression levels were also analyzed by immunoblotting using
the appropriate antibodies. ERK2 was analyzed as a control
for protein loading (bottom panel). B, p16Ink4a mRNA ex-
pression levels were measured by real-time PCR. Fold
changes in the levels of p16Ink4a are presented in graphical
form. Statistical analysis (Student’s t test) was performed as
described in the Materials and Methods section (*p  0.05).
ERK, extracellular signal-regulated kinase; mRNA, messenger
RNA; PCR, polymerase chain reaction.
FIGURE 6. Proposed model of human lung adenocarci-
noma development in the presence of p38 MAPK activity.
p38 activation may be triggered by oncogenic stresses and
transduce signals that activate p16Ink4a expression, resulting
in suppression of tumor growth. Tumors may evade tumor
suppression through the inhibition of p16Ink4a expression,
mediated either by the induction of Bmi-1 or by promoter
methylation. MAPK, mitogen-activated protein kinase.
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p16Ink4a, which frequently occurs in NSCLC (48%)51 and
lung cancer cell lines,24 would be able to account for
another mechanism of failure of p16Ink4a under p38
activation in NSCLC. The interesting possibility that any
link of frequent homozygous deletion in p16Ink4a with
constant p38 activation by oncogenic stimulation in
NSCLC remains to be determined.
In summary, our results demonstrate that the abro-
gation of p16Ink4a expression by either Bmi-1 induction
or p16Ink4a methylation may be associated with cancer
development in the presence of high levels of p38 activity.
These novel results provide us with important insight into
the apparent contradiction of activated p38 in lung cancer
cells, considering the profound tumor-suppressive effects
of p38. Our findings, although helpful, are expected to lead
to more extensive studies, in which they will be confirmed
in a clinical setting.
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